Clinical Trial Update: A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) [Phase 3]

View source ↗

Summary

Phase 3 cardiovascular outcome trial evaluating the safety of Survodutide (BI 456906) in overweight or obese individuals has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity | Phase 3 | Status: COMPLETED